Drug Type Synthetic peptide |
Synonyms EphA2-RLT(QIC) |
Target |
Action antagonists |
Mechanism EphA2 antagonists(Ephrin type-A receptor 2 antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Ovarian Cancer | Preclinical | South Korea | 28 Sep 2024 |